Ascendis Pharma (ASND) Misses Q1 EPS by 14c, Miss on Revenues

Ascendis Pharma (NASDAQ: ASND) reported Q1 EPS of ($0.87), $0.14 worse than the analyst estimate of ($0.73). Revenue for the quarter came in at $416 thousand versus the consensus estimate of $1.37 million.

For earnings history and earnings-related data on Ascendis Pharma (ASND) click here.

You May Also Be Interested In

• Concentrix Corporation (CNXC) Misses Q2 EPS by 1c; Guides lower than expectations
• Freedom Broker Starts American States Water (AWR) at Hold
• Apogee Enterprises (APOG) Tops Q1 EPS by 16c, Beats on Revenue; Offers FY27 Guidance